1 Hr
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
1 Hrالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
1 HrReady to play
Ready to play
Two phase 3 clinical trials involving more than 1,000 participants found that the experimental once-weekly injectable drug retatrutide helped people with overweight or obesity ease knee osteoarthritis pain while losing weight. Those receiving the highest dose lost about 25 percent of their body weight, and roughly two-thirds of participants saw their pain fall by at least 50 percent, compared with 38 percent of those given a placebo. Researchers believe the weight loss reduced pressure on the joint, but emphasized that diet, exercise and lifestyle changes remain the first-line options, along with the importance of preserving muscle mass. If approved by the U.S. Food and Drug Administration, the drug could become an option for people who do not benefit from traditional approaches.
Notice: This Is an AI-Generated Summary
Comments (0)